ft 21 jul 93 uk compani news sb futur cloud expiri us patent smithklin beecham abil overcom inevit damag inflict next may expiri us patent tagamet best sell product crucial group futur tagamet anti ulcer treatment world best sell drug still gener sale dollar 1 1bn pound 730m last year dollar 650m us divis turnov last year pound 2 8bn bad news anyon think patent expiri substanti impact sb go disappoint drug still substanti sale profit say mr jan leschley head sb pharmaceut arm group chief execut design sb strategi launch counter version tagamet gener growth new product slight hiccup first element strategi merger smithklin us uk group beecham american compani sold otc distribut right tagamet uk wellcom mr leschley refus discuss issu describ delic meanwhil compani lodg dossier us food drug administr medicin make switch otc statu gener growth new product mr leschley stress success paxil new anti depress relafen arthriti drug kytril anti nausea product havrix hepat vaccin gener pound 96m new sale second quarter compar pound 212m whole last year us launch paxil outpac market leader among advanc select serotonin uptak inhibitor eli lilli prozac sb drug captur 15 6 per cent new prescript second quarter compar 6 per cent februari launch medicin 24 per cent whole uk anti depress market 20 per cent dutch market relafen perform us describ mr leschley tremend kytril well roll havrix extrem success said howev sb strategi continu growth may held worsen environ drug compani european drug sale second quarter 1 per cent turnov germani itali healthcar reform introduc fell 9 per cent 15 per cent respect franc uk sale 10 per cent 8 per cent mr leschley said optimist germani itali full year doubt franc uk spain see cost contain measur introduc near futur sb respons like merck world largest drug group yesterday announc redund said mr leschley plan whatsoev make across board lay off say redund select pocket laid 100 sale repres germani said